Welcome to our dedicated page for Medpace Holdings SEC filings (Ticker: MEDP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Medpace Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Medpace Holdings's regulatory disclosures and financial reporting.
August J. Troendle, President, CEO and 10% owner of Medpace Holdings, reported open-market sales of 7,238 common shares on July 27-28, 2026, executed under a limit order placed during an open window period. The trades comprised 3,728 shares at a weighted average price of $600.85 (range $600.00–$603.495) and 3,510 shares at a weighted average price of $600.01 (range $600.00–$600.45). A separate entry lists 4,733,019 common shares held indirectly by Medpace Investors, LLC, over which he has sole voting and investment control and may be deemed to indirectly beneficially own, while disclaiming beneficial ownership beyond his pecuniary interest. The filing states these transactions were not made under a Rule 10b5-1 trading plan.
Medpace Holdings, Inc. executive Susan E. Burwig, Exec. VP, Operations, reported selling 7,500 shares of Common Stock on 2026-07-28 at $600 per share in a transaction described as open market or private.
After the sale, she directly owned 62,984 shares. The trade was executed under a limit order placed during an open window period.
Medpace Holdings, Inc. filed a notice for the potential sale of common stock under a Form 144/A. The filing lists Fidelity Brokerage Services LLC as broker and indicates a proposed sale of up to 11,000 common shares on NASDAQ. These shares relate to a Stock Option Exercise dated 12/06/2024, with the sale targeted around 07/23/2026 for cash consideration.
Jesse J. Geiger, a shareholder of Medpace Holdings, Inc., has filed to sell 4,000 shares of Medpace common stock through Fidelity Brokerage Services LLC on or after July 28, 2026 on NASDAQ. These shares were acquired via a stock option exercise for cash on December 6, 2024. The filing also notes a prior sale of 11,000 shares of Medpace common stock on July 23, 2026 for total proceeds of $6,950,877.79.
Medpace Holdings, Inc. reported second quarter 2026 revenue of $707.3 million, up 17.2% from $603.3 million a year earlier, with backlog of $3,014.2 million, up 4.9%. Net new business awards reached $795.7 million, 28.2% above the prior-year period and producing a net book-to-bill ratio of 1.13x. GAAP net income was $121.4 million, or $4.25 per diluted share, versus $90.3 million, or $3.10 per diluted share, and net income margin improved to 17.2% from 15.0%. EBITDA rose to $153.4 million, representing a 21.7% margin.
For the six months ended June 30, 2026, revenue was $1,413.9 million, up 21.7% year over year, with GAAP net income of $245.2 million and EBITDA of $302.8 million. Cash and cash equivalents were $502.7 million, and operating activities generated $162.0 million of cash in the quarter. Medpace repurchased 705,616 shares for $294.7 million, leaving $527.0 million available under its share repurchase program. For full year 2026, the company forecasts revenue of $2.805–$2.885 billion, GAAP net income of $494.0–$514.0 million, EBITDA of $618.0–$642.0 million, and diluted EPS of $17.25–$17.95.
Medpace Holdings director Cornelius P. McCarthy III exercised restricted stock units into common shares. He acquired 28 shares of Medpace common stock through the conversion of restricted stock units, bringing his direct common stock holdings to 10,352 shares. Following this transaction, he continues to hold 56 restricted stock units that each represent a contingent right to receive one share of Medpace common stock upon future vesting.